Senseonics Holdings Inc (NYSEAMERICAN:SENS) saw a large increase in short interest in August. As of August 31st, there was short interest totalling 32,804,800 shares, an increase of 9.7% from the July 31st total of 29,900,000 shares. Currently, 33.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 2,060,000 shares, the days-to-cover ratio is currently 15.9 days.
Shares of SENS stock opened at $1.11 on Monday. Senseonics has a 52 week low of $0.92 and a 52 week high of $4.89.
Senseonics (NYSEAMERICAN:SENS) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). The business had revenue of $4.61 million for the quarter, compared to analyst estimates of $4.53 million. The firm’s quarterly revenue was up 27.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.16) EPS.
A number of hedge funds have recently made changes to their positions in SENS. Bank of Montreal Can lifted its stake in Senseonics by 236.4% in the 2nd quarter. Bank of Montreal Can now owns 14,513 shares of the company’s stock worth $29,000 after purchasing an additional 10,199 shares in the last quarter. D. E. Shaw & Co. Inc. purchased a new stake in Senseonics in the 2nd quarter worth $33,000. Creative Planning purchased a new stake in Senseonics in the 1st quarter worth $34,000. Centaurus Financial Inc. lifted its stake in Senseonics by 40,551.2% in the 2nd quarter. Centaurus Financial Inc. now owns 16,667 shares of the company’s stock worth $34,000 after purchasing an additional 16,626 shares in the last quarter. Finally, Moors & Cabot Inc. purchased a new stake in shares of Senseonics during the 1st quarter valued at about $38,000. Institutional investors and hedge funds own 30.66% of the company’s stock.
SENS has been the topic of a number of analyst reports. Raymond James cut shares of Senseonics from an “outperform” rating to a “market perform” rating in a research note on Friday, July 5th. BTIG Research restated a “buy” rating and set a $2.00 target price on shares of Senseonics in a research note on Sunday, August 11th. Finally, Piper Jaffray Companies set a $2.00 target price on shares of Senseonics and gave the company a “hold” rating in a research note on Wednesday, September 4th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $2.00.
Senseonics Holdings, Inc, a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days.
Further Reading: Rule of 72
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.